Related Experiment Video
Updated: Aug 9, 2026
Isolation and Characterization of Adult Cardiac Fibroblasts and Myofibroblasts
Published on: March 12, 2020
Sequential FIB-4-based testing limits detection of fibrotic MASLD despite optimized ELF thresholds
Alina M Allen1, Olivia J Bobek2, Rachel E Canning2
1Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background:
Societal guidance recommends sequential noninvasive testing for metabolic dysfunction-associated steatotic liver disease (MASLD), using Fibrosis-4 (FIB-4) ≥1.3 as a gatekeeper before second-line assessment with the Enhanced Liver Fibrosis (ELF) score (<7.7 as a rule-out). The impact of this pathway design on the detection of fibrotic MASH remains uncertain. We aimed to evaluate the performance of guideline-endorsed sequential testing and to determine optimized ELF thresholds within alternative strategies.
Methods:
In this prospective study, patients with or at risk for MASLD underwent FIB-4, ELF testing, magnetic resonance elastography (MRE), and liver biopsy within 1 month. Fibrotic MASLD was defined as fibrosis stage ≥2 on histology or liver stiffness ≥3.1 kPa on MRE. Diagnostic performance of ELF was assessed, and sequential (ELF applied after FIB-4 ≥1.3) and concurrent (either test positive) testing strategies were compared.Results:Among 186 participants (median age 51 years; 69% women), fibrotic MASLD was present in 71 (38%). ELF demonstrated AUROC 0.77 (95% CI 0.70-0.84); the cohort-derived cutoff was 9.4 (80% sensitivity, 65% specificity). Lower cutoffs (8.7 and 7.7) increased sensitivity (≥90% and 100%) but low specificity (34% and 4%). FIB-4 ≥1.3 showed limited sensitivity (57%), resulting in 43% of fibrotic MASH cases being excluded from second-line testing. Sequential application of ELF, therefore, failed to overcome this sensitivity ceiling. A concurrent strategy using FIB-4 ≥1.3 or ELF ≥9.4 improved sensitivity to 87% with 64% specificity.
Conclusions:
Sequential FIB-4-based testing substantially limits the detection of fibrotic MASLD due to gatekeeping sensitivity constraints. Concurrent first-line testing with FIB-4 and ELF improves case identification, underscoring the importance of pathway design in optimizing noninvasive fibrosis assessment.
Insights
Sequential testing for metabolic dysfunction-associated steatotic liver disease (MASLD) misses many fibrotic cases. Concurrent testing with Fibrosis-4 (FIB-4) and Enhanced Liver Fibrosis (ELF) scores improves detection of advanced fibrosis in MASLD patients.
Area of Science:
- Hepatology
- Biomarkers
- Diagnostic Accuracy
Background:
- Current guidelines recommend sequential noninvasive testing for metabolic dysfunction-associated steatotic liver disease (MASLD).
- This involves using Fibrosis-4 (FIB-4) as an initial screen before Enhanced Liver Fibrosis (ELF) score assessment.
- The impact of this sequential approach on detecting fibrotic MASLD is not well understood.
Purpose of the Study:
- To evaluate the performance of guideline-recommended sequential noninvasive testing for MASLD.
- To determine optimal ELF score thresholds for alternative diagnostic strategies.
- To compare the diagnostic accuracy of sequential versus concurrent testing strategies.
Main Methods:
- Prospective study involving 186 patients with or at risk for MASLD.
- Patients underwent FIB-4, ELF testing, magnetic resonance elastography (MRE), and liver biopsy.
- Diagnostic performance was assessed, comparing sequential (FIB-4 then ELF) and concurrent (FIB-4 or ELF) strategies.
Main Results:
- Fibrotic MASLD was present in 38% of participants.
- The guideline-recommended sequential strategy using FIB-4 ≥1.3 excluded 43% of fibrotic MASLD cases due to low sensitivity.
- A concurrent strategy (FIB-4 ≥1.3 or ELF ≥9.4) improved sensitivity to 87% with 64% specificity.
Conclusions:
- Sequential FIB-4-based testing significantly limits the detection of fibrotic MASLD.
- Concurrent first-line testing using FIB-4 and ELF enhances the identification of fibrotic MASLD.
- Optimizing diagnostic pathway design is crucial for accurate noninvasive fibrosis assessment.
